Critical appraisal of revised cholesterol guidelines for the very high-risk patient

References Papers of special note have been highlighted as:• of interest•• of considerable interest

• Grundy SM, Cleeman JI, Merz CN, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110, 227–239 (2004).
   Google Scholar
• The Heart Protection Study Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360, 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• Cannon CP, McCabe CH, Belder R, Breen J, Braunwald E. Design of the PRavastatin Or atorVastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. Am. J. Cardiol. 89, 860–861 (2002).
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Blazing MA, Wiviott SD et al. Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. J. Am. Med. Assoc. 292, 1307–1316 (2004).
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 335, 1001–1009 (1996).
   PubMed Web of Science ®Google Scholar
• The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383–1389 (1994).
   PubMed Web of Science ®Google Scholar
• The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339, 1349–1357 (1998).
   PubMed Web of Science ®Google Scholar
• Girman CJ, Rhodes T, Mercuri M et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am. J. Cardiol. 93, 136–141 (2004).
   PubMed Web of Science ®Google Scholar
• Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 361, 2005–2016 (2003).
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Thomason MJ, Mackness MI et al. Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes. Diabet. Med. 19, 201–211 (2002).
   PubMed Web of Science ®Google Scholar
• Waters DD, Guyton JR, Herrington DM et al. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am. J. Cardiol. 93, 154–158 (2004).
   PubMed Web of Science ®Google Scholar
• MacMahon M, Kirkpatrick C, Cummings CE et al. A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Nutr. Metab. Cardiovasc. Dis. 10, 195–203 (2000).
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Faergeman O, Holme I, Olsson AG, Tikkanen MJ. Effect of greater LDL-C reductions on prognosis: the Incremental Decrease in End point through Aggressive Lipid lowering (IDEAL) trial. Atherosclerosis 144(Suppl. 1), 38 (1999).
   Google Scholar
• Rubins HB, Robins SJ, Collins D et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch. Intern. Med. 162, 2597–2604 (2002).
   PubMed Web of Science ®Google Scholar
• Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317, 1237–1245 (1987).
   PubMed Web of Science ®Google Scholar
• Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102, 21–27 (2000).
   PubMed Web of Science ®Google Scholar
• Keech AC and the FIELD study invesstigators. The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event-Lowering in Diabetes (FIELD) study. Cardiovasc. Diabetol 3, 9(2004).
   PubMedGoogle Scholar
• Halimi S, Charpentier G, Grimaldi A et al. Effect on compliance, acceptability of blood glucose self-monitoring and HbA(1c) of a self-monitoring system developed according to patient’s wishes. The ACCORD study. Diabetes Metab. 27, 681–687 (2001).
   PubMed Web of Science ®Google Scholar
• Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J. Am. Med. Assoc. 285, 2486–2497 (2001).
   PubMed Web of Science ®Google Scholar
• Andrews TC, Ballantyne CM, Hsia JA, Kramer JH. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am. J. Med. 111, 185–191 (2001).
   PubMed Web of Science ®Google Scholar
• Brown AS, Bakker-Arkema RG, Yellen L et al. Treating patients with documented atherosclerosis to National Cholesterol Education Program recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J. Am. Coll. Cardiol. 32, 665–672 (1998).
   PubMed Web of Science ®Google Scholar
• Jones PH, Davidson MH, Stein EA et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am. J. Cardiol. 92, 152–160 (2003).
   PubMed Web of Science ®Google Scholar
• Gagne C, Bays HE, Weiss SR et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am. J. Cardiol. 90, 1084–1091 (2002).
   PubMed Web of Science ®Google Scholar
• Hunninghake D, Insull W Jr, Toth P et al. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL-cholesterol additively. Atherosclerosis 158, 407–416 (2001).
   PubMed Web of Science ®Google Scholar
• Feldman T, Koren M, Insull W Jr et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am. J. Cardiol. 93, 1481–1486 (2004).
   PubMed Web of Science ®Google Scholar
• Rosenson RS. Current overview of statin-induced myopathy. Am. J. Med. 116, 408–416 (2004).
   PubMed Web of Science ®Google Scholar
• Rosenson R. Statins: can the new generation make an impression? Expert Opin. Emerg. Drugs 9(2), 269–279 (2004).
   Google Scholar
• Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 106, 1930–1937 (2002).
   Google Scholar
• Kuller L, Arnold A, Tracy R et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the Cardiovascular Health Study. Arterioscler. Thromb. Vasc. Biol. 22, 1175–1180 (2002).
   PubMed Web of Science ®Google Scholar
• Otvos JD, Cromwell W, Shalaurova I, Schaefer EJ. LDL particles, but not LDL-cholesterol, are highly elevated in the metabolic syndrome: results from the Framingham Offspring Study. Circulation 108(Suppl. IV), 740–741 (2003).
   PubMedGoogle Scholar
• Otvos JD, Collins D, Freed M et al. LDL and HDL particle subclasses are in dependent predictors of cardiovascular events in the Veteran Affairs HDL Intervention Trial. Circulation 106(Suppl. II), 729 (2002).
   PubMedGoogle Scholar